	US 12,220,488 B2
	Cannabinoid dosage forms
Justin Davis, Alamosa, CO (US); and Richard P. Baker, Anaheim, CA (US)
Assigned to TGC Network LLC, Saguache, CO (US)
Filed by TGC Network LLC, Alamosa, CO (US)
Filed on Nov. 19, 2021, as Appl. No. 17/531,430.
Application 17/531,430 is a continuation of application No. 16/230,507, filed on Dec. 21, 2018, granted, now 11,179,340.
Claims priority of provisional application 62/612,172, filed on Dec. 29, 2017.
Prior Publication US 2022/0071910 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/20 (2006.01); A61K 31/05 (2006.01)

CPC A61K 9/2095 (2013.01) [A61K 9/2077 (2013.01); A61K 31/05 (2013.01); A61K 9/2009 (2013.01); A61K 9/2031 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01)]

8 Claims

1. A dosage form, consisting of cannabigerol isolate crystals, cannabinol isolate crystals, or Δ9-tetrahydrocannabinol isolate crystals each having a purity of at least 90% and a particle size of about 200 microns to about 600 microns, each of said cannabigerol isolate crystals, said cannabinol isolate crystals, or said Δ9-tetrahydrocannabinol isolate crystals pressed into a tablet.